Efficacy, Safety, and Tolerability of Fosmetpantotenate (RE-024), A Phosphopantothenate Replacement Therapy, in Pantothenate Kinase-Associated Neurodegeneration (PKAN) Patients: A Randomized, Double Blind, Placebo Controlled Study With an Open Label Extension

Trial Profile

Efficacy, Safety, and Tolerability of Fosmetpantotenate (RE-024), A Phosphopantothenate Replacement Therapy, in Pantothenate Kinase-Associated Neurodegeneration (PKAN) Patients: A Randomized, Double Blind, Placebo Controlled Study With an Open Label Extension

Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Fosmetpantotenate (Primary)
  • Indications Pantothenate kinase-associated neurodegeneration
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms FORT
  • Sponsors Retrophin
  • Most Recent Events

    • 25 Jul 2017 According to a Retrophin media release, the first patient has been dosed in this study.
    • 25 May 2017 According to a Retrophin media release, data from the study will be presented at the 54th European Renal Association European Dialysis and Transplant Association (ERA-EDTA) Congress 2017.
    • 25 Apr 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top